North Carolina Headlines

(Albany, New York) – 21st Sep 2026 – DelveInsight’s latest report, “Glioma Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the global Glioma treatment market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, treatment practices, market dynamics, marketed and emerging therapies, competitive intelligence, drug uptake, reimbursement, unmet needs, and future market opportunities through 2036.

According to DelveInsight, the Glioma treatment market across the 7MM was valued at over USD 1 billion in 2025 and is projected to grow at approximately 15% CAGR during 2022–2036. The United States accounted for the largest share of the Glioma market in 2025, representing approximately 65% of the total market.

Key Takeaways from the Glioma Market

• The 7MM Glioma treatment market exceeded USD 1 billion in 2025.
• The market is projected to grow at approximately 15% CAGR during 2022–2036.
• The United States accounted for approximately 65% of the total Glioma market in 2025.
• The United States recorded approximately 51,000 Glioma incident cases across the 7MM in 2025.
• In the US, high-grade glioma accounted for approximately 16,700 cases, compared with approximately 4,170 low-grade glioma cases in 2025.
• Among all glioma grades in the US, Grade IV accounted for approximately 70% of incident cases, followed by Grade II at approximately 15%, while Grade I represented approximately 7%.
• Among the EU4 and UK, Germany generated the highest Glioma market revenue at approximately USD 95 million in 2025, while Spain had the lowest share.
• In Japan, OPTUNE ± temozolomide captured the highest Glioma treatment market size in 2025.
• Approved therapies include TEMODAR (temozolomide), AVASTIN (bevacizumab), OPTUNE, TAFINLAR + MEKINIST, VORANIGO (vorasidenib), and MODEYSO (dordaviprone).
• Emerging therapies include DCVax-L, AV-GBM-1, Enzastaurin, Paxalisib, LAM561, SurVaxM, DNX-2401, ITI-1000, Berubicin, and others.
• Key companies include Novocure, Genentech, Merck, Daiichi Sankyo, Novartis, Bayer, Servier Pharmaceuticals, Kazia Therapeutics, Aivita Biomedical, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, and Immunomic Therapeutics.

Keen to know more about the Glioma market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, competitive intelligence, and forecast analysis. https://www.delveinsight.com/sample-request/glioma-market

Key Factors Driving the Glioma Market

Rising Glioma Prevalence

The increasing incidence and prevalence of glioma, particularly aggressive forms such as glioblastoma, remain important factors supporting market growth. Although glioma is a relatively rare cancer, its high mortality and recurrence rates create a sustained population requiring ongoing treatment and disease management.

Improved diagnostic capabilities and an aging population are also contributing to the identification and management of glioma cases across major markets.

Advancements in Treatment Approaches

The glioma treatment landscape has evolved beyond conventional surgery, radiation, and chemotherapy. The introduction of tumor treating fields, targeted therapies, immunotherapies, cancer vaccines, and oncolytic viruses is broadening treatment options for patients with different molecular and clinical characteristics.

The emergence of biomarker-driven therapies is particularly important in low-grade and molecularly defined gliomas.

Growing Opportunities in Precision Medicine

Precision medicine is increasingly shaping glioma treatment. Therapies targeting specific genetic alterations, including IDH mutations, BRAF V600E mutations, and H3 K27M mutations, are expanding treatment options for molecularly selected populations.

VORANIGO (vorasidenib) for IDH-mutant Grade 2 astrocytoma and oligodendroglioma and MODEYSO (dordaviprone) for H3 K27M-mutant diffuse midline glioma illustrate the movement toward biomarker-defined treatment.

Expansion of Immunotherapy and Cancer Vaccines

Cancer vaccines and cell-based immunotherapies represent an important segment of the emerging glioma pipeline. Candidates such as DCVax-L, AV-GBM-1, SurVaxM, and ITI-1000 are being investigated for their potential to generate durable antitumor immune responses.

These approaches are particularly relevant because conventional therapies continue to provide limited long-term disease control in high-grade glioma.

Development of Oncolytic Virus Therapies

Oncolytic viruses are another growing area of innovation. DELYTACT (teserpaturev), DNX-2401, and Ofranergene Obadenovec are designed to exploit tumor-specific biology while stimulating an antitumor immune response.

The continued development of these approaches could broaden therapeutic options for patients with recurrent or treatment-resistant disease.

Competitive Landscape

The Glioma market consists of established therapies alongside a diverse pipeline of targeted agents, immunotherapies, cancer vaccines, oncolytic viruses, and novel drug-delivery approaches.

Key companies include:

• Novocure
• Genentech
• Merck
• Daiichi Sankyo
• Novartis
• Bayer
• Servier Pharmaceuticals
• Kazia Therapeutics
• Aivita Biomedical
• Northwest Therapeutics
• VBL Therapeutics
• Laminar Pharmaceuticals
• Immunomic Therapeutics

The marketed landscape includes TEMODAR, AVASTIN, OPTUNE, TAFINLAR + MEKINIST, VORANIGO, and DELYTACT, while the emerging pipeline includes DCVax-L, AV-GBM-1, Enzastaurin, Paxalisib, LAM561, SurVaxM, DNX-2401, ITI-1000, and Berubicin.

Recent Developments in the Glioma Market

• January 2026: Bayer reported ongoing evaluation of regorafenib in glioblastoma through platform trials such as GBM AGILE, supporting continued investigation in newly diagnosed and recurrent settings.
• November 2025: Northwest Biotherapeutics advanced regulatory engagement for DCVax-L following Phase III data demonstrating improved overall survival in glioblastoma patients.
• September 2025: Daiichi Sankyo continued post-marketing and clinical development activities for teserpaturev (DELYTACT), an oncolytic virus approved in Japan for malignant glioma.
• August 2025: The US FDA granted accelerated approval to dordaviprone (MODEYSO) for patients aged 1 year and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
• November 2025: Data from the Phase I REGOMA-2 study indicated that regorafenib in combination with temozolomide and radiotherapy was tolerable in patients with MGMT-methylated, IDH wild-type glioblastoma.
• January 2024: TAE Life Sciences and AIVITA Biomedical announced a partnership focused on addressing challenges associated with obtaining high-quality glioblastoma tissue samples for development of novel cancer therapeutics.

What is Glioma?

Glioma is the most common central nervous system (CNS) neoplasm and originates from glial cells. These tumors are often diffusely infiltrative and can affect surrounding brain tissue. Common glioma types include astrocytomas, ependymomas, and oligodendrogliomas.

Gliomas are classified into Grades I–IV based on their biological and histological characteristics. Glioblastoma (Grade IV) represents the most aggressive form, while Grade I tumors such as pilocytic astrocytomas are generally less malignant.

Genetic alterations play an important role in glioma development and classification. Important genes and molecular alterations include TP53, PTEN, BRAF, and IDH1, among others. Molecular characterization is increasingly important for diagnosis, prognosis, and treatment selection.

Diagnosis of Glioma

Glioma diagnosis generally begins with neurological evaluation and imaging. Common diagnostic approaches include:

• Neurological examination
• Magnetic resonance imaging (MRI)
• Computed tomography (CT)
• Angiography in selected cases
• Surgical biopsy
• Histopathological examination
• Molecular and biomarker testing

MRI is an important imaging modality because it provides detailed visualization of brain structures and assists in differentiating brain tumors. When imaging suggests glioma, biopsy and molecular analysis can help establish tumor type and grade and guide treatment selection.

Current Treatment Landscape

Glioma treatment depends on the tumor type, grade, molecular characteristics, location, size, and patient-specific factors. The standard treatment approach generally involves maximum safe surgical resection followed by radiation therapy and chemotherapy when clinically appropriate.

Temozolomide (TEMODAR)

Temozolomide remains a cornerstone of glioma treatment, particularly for glioblastoma. It is an oral alkylating agent that crosses the blood–brain barrier and damages tumor-cell DNA. It is commonly used with radiation therapy in newly diagnosed glioblastoma and as maintenance therapy.

Bevacizumab (AVASTIN)

Bevacizumab is a VEGF inhibitor that suppresses tumor angiogenesis. It remains an important treatment option, particularly in recurrent glioma, although its effect on overall survival remains limited.

OPTUNE

OPTUNE is a tumor treating fields device that uses alternating electrical fields to interfere with tumor-cell division. It is used alongside chemotherapy in eligible patients and has become an important component of glioblastoma treatment.

TAFINLAR + MEKINIST

The combination of dabrafenib (TAFINLAR) and trametinib (MEKINIST) targets the MAPK pathway and is used for BRAF V600E-mutant gliomas. Its availability represents an important advancement in biomarker-driven treatment.

VORANIGO (Vorasidenib)

Vorasidenib is a brain-penetrant inhibitor targeting mutant IDH1 and IDH2. The US FDA approved VORANIGO in August 2024 for patients aged 12 years and older with Grade 2 astrocytoma or oligodendroglioma harboring susceptible IDH1 or IDH2 mutations following surgery.

MODEYSO (Dordaviprone)

Dordaviprone received accelerated FDA approval in August 2025 for adult and pediatric patients aged 1 year and older with H3 K27M-mutant diffuse midline glioma with progressive disease following prior therapy. It represents a targeted treatment option for this molecularly defined, aggressive tumor.

Glioma Epidemiology

According to DelveInsight’s estimates, Glioma incident cases across the 7MM were approximately 51,000 in 2025. The epidemiological analysis evaluates total incident cases as well as grade-, age-, and type-specific disease burden across the seven major markets.

Key epidemiological findings include:

• Approximately 51,000 Glioma incident cases were recorded across the 7MM in 2025.
• In the US, high-grade glioma accounted for approximately 16,700 cases, compared with approximately 4,170 low-grade glioma cases.
• Grade IV glioma represented approximately 70% of US incident cases in 2025.
• Grade II glioma accounted for approximately 15% of US cases, while Grade I represented approximately 7%.
• In the US, glioblastoma was more prevalent among adults than pediatric patients.
• In Japan, approximately 2,735 adult glioblastoma cases were reported in 2025.

Epidemiology Segmentation

DelveInsight segments Glioma epidemiology into:

• Total Glioma Incident Cases
• Glioma Grade-specific Incident Cases
• Glioma Age-specific Incident Cases
• Glioma Type-specific Incident Cases

Unmet Needs in Glioma

Despite significant advances in diagnosis and treatment, important unmet needs remain:

1. Lack of effective curative treatment options
2. Limited diagnostic accuracy in certain disease settings
3. Need for improved supportive care and patient information
4. High clinical trial failure rates
5. Need for larger multicenter clinical studies
6. Need for effective target inhibition
7. Challenges in delivering drugs across the blood–brain barrier
8. High recurrence rates and poor prognosis in high-grade disease

These challenges are driving research into precision medicine, immunotherapy, cancer vaccines, oncolytic viruses, novel drug-delivery platforms, and combination treatment strategies.

Scope of the Glioma Market Report

• Study Period: 2022–2036
• Historical Period: 2022–2025
• Forecast Period: 2026–2036
• Base Year: 2026
• Geographies: US, Germany, France, Italy, Spain, UK, and Japan
• 7MM Glioma Incident Cases, 2025: ~51,000
• 7MM Glioma Treatment Market, 2025: >USD 1 billion
• Market CAGR: ~15% during 2022–2036
• US Market Share, 2025: ~65%
• Germany Market Revenue, 2025: ~USD 95 million
• Epidemiology Segmentation: Total incident cases, grade-specific incident cases, age-specific incident cases, and type-specific incident cases
• Market Segmentation: Region/geographies and drugs/therapies
• Key Companies: Novocure, Genentech, Merck, Daiichi Sankyo, Novartis, Bayer, Servier Pharmaceuticals, Kazia Therapeutics, Aivita Biomedical, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, and Immunomic Therapeutics
• Key Marketed Therapies: Dordaviprone (MODEYSO), Vorasidenib (VORANIGO), Bevacizumab (AVASTIN), Temozolomide (TEMODAR), TAFINLAR + MEKINIST, and DELYTACT
• Key Emerging Therapies: Regorafenib, AV-GBM-1, Enzastaurin, DCVax-L, LAM561, Durvalumab, DNX-2401, ITI-1000, IGV-001, SurVaxM, Berubicin, and others
• Analysis: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, and patient burden assessment
• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, long-term market forecasting, regional market outlook, patient burden assessment, treatment addressable market, competitive landscape, company insights, therapy uptake, and peak patient share analysis.

To Know More About the Glioma Market Report

Glioma Market Insight, Epidemiology and Market Forecast – 2036

Table of Contents

1. Report Introduction
2. Executive Summary
3. Key Events
4. Epidemiology and Market Methodology
5. Glioma Disease Overview
6. Causes, Risk Factors, Signs and Symptoms
7. Classification and Grading of Glioma
8. Diagnosis and Diagnostic Algorithm
9. Treatment Landscape
10. Current Treatment Guidelines
11. Marketed Therapies
12. Emerging Therapies and Pipeline Analysis
13. Epidemiology and Patient Burden
14. Patient Journey
15. Market Size and Forecast
16. Drug Uptake and Patient Share
17. Competitive Landscape
18. Market Drivers and Barriers
19. Unmet Medical Needs
20. Market Access and Reimbursement
21. Pricing and Analogue Assessment
22. KOL and SME Insights
23. SWOT and Conjoint Analysis
24. Regional Market Analysis
25. Company and Therapy Profiles
26. Market Outlook
27. Conclusions and Strategic Insights

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services